David Liu (courtesy Broad Institute)
July 13, 2021 05:00 AM EDTUpdated 03:11 PM
Financing
Startups
Cell/Gene Tx

David Liu takes the wraps off $315M launch round for Prime Med­i­cine and new CRISPR tech that gave Bob Nelsen a 'holy crap' mo­ment

Jason Mast

Editor

Ven­ture cap­i­tal­ist Bob Nelsen was sit­ting on his couch two sum­mers ago when he got a call from a fa­mous sci­en­tist, who mat­ter-of-fact­ly ex­plained that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times